Date: 2013-12-04
Type of information: Collaboration agreement
Compound:
Company: Lucane Pharma (France) Medunik Canada (Canada)
Therapeutic area: Rare diseases - Genetic diseases - Metabolic diseases - Liver diseases
Type agreement: collaboration
Action mechanism:
Disease: urea cycle disorder
Details: * On December 4, 2013, Medunik Canada, a pharmaceutical company specialized in orphan drugs, and Lucane Pharma, a French niche pharmaceutical company, have concluded an exclusive collaboration agreement. Through this agreement, Medunik Canada receives the exclusive Canadian rights to market and distribute a new therapeutic option for patients suffering from Urea Cycle Disorders (UCD), a group of rare diseases involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate sythetase. This therapeutic option is taste-free, which facilitates medication and favours compliance to treatment.
Financial terms:
Latest news:
